'On standalone basis

Quarter ended September 2025 compared with Quarter ended September 2024.

Net sales (including other operating income) of Supriya Lifescience has increased 20.31% to Rs 199.83 crore.  Operating profit margin has declined from 38.96% to 36.36%, leading to 12.25% rise in operating profit to Rs 72.65 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 33.89% to 29.63%.   Employee cost increased from 10.84% to 11.95%.   Other expenses rose from 19.66% to 22.94%.   

Other income up 8.33% to Rs 2.73 crore.  PBIDT rose 12.11% to Rs 75.38 crore.  Provision for interest fell 2.33% to Rs 0.42 crore.  Loan funds declined from Rs 5.51 crore as of 30 September 2024 to Rs 5.23 crore as of 30 September 2025.  Inventories rose to Rs 142.81 crore as of 30 September 2025 from Rs 107.99 crore as of 30 September 2024. &nbs...

• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026
• 

  (09-Jan-2026)

  Elecon Engineering Company

  Sales up 4%, net down 33%
• 

  (19-Nov-2025)

  Monte Carlo Fashions

  Net sales up 13.2% YoY to Rs 248.7 crore in Q2FY2026
• 

  (17-Nov-2025)

  Eicher Motors

  OP surged 39%